Abstract: The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
Type:
Grant
Filed:
August 27, 2004
Date of Patent:
October 24, 2006
Assignee:
Allergan, Inc.
Inventors:
George R. Ehring, Joseph S. Adorante, John E. Donello, Larry A. Wheeler, Thomas Malone
Abstract: The present invention relates to an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine disorders, for example gonadotrophin related illnesses. Preferably, the agent comprises at least a portion of a botulinum toxin.
Abstract: Methods for treating endocrine disorders and for inhibiting gametogenesis by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.
Abstract: According to the invention there is provided a compound the formula I;
wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
Abstract: Methods for treating the hypothyroidism of Hashimoto's thyroiditis by local administration of a Clostridial toxin, such as a botulinum toxin, to the thyroid gland of a patient.
Abstract: A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I,
wherein Y is (CH2)x; Z is selected from the group consisting of
x is an integer of 1 or 2; n is 0 or 1; R2 is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein t
Type:
Grant
Filed:
August 5, 2002
Date of Patent:
November 16, 2004
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Achim H-P Krauss, David F. Woodward
Abstract: The present invention provides a compound represented by the general formula I;
wherein A, Ar, X, Z, n, x, y, R and R3 are as defined in the specification.
Type:
Grant
Filed:
January 26, 2004
Date of Patent:
November 2, 2004
Assignee:
Allergan, Inc.
Inventors:
David W. Old, Thang D. Dinh, Robert M. Burk
Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.
Abstract: Methods for treating the hypothyroidism of Hashimoto's thyroiditis by local administration of a neurotoxin, such as a botulinum toxin, to the thyroid gland of a patient.
Abstract: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.
Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;
wherein hatched lines represent the &agr; configuration, a triangle represents the &bgr; configuration, a wavy line represents the &agr; configuration or the &bgr; configuration and a dotted line represents the presence or absence of a double bond;
A and B are independently selected from the group consisting of O, S and CH2;
provided that at least one of A or B is S;
D represents a covalent bond or CH2, O, S or NH;
X is CO2R, CONR2, CH2OR, P(O)(OR)2, CONRSO2R SONR2 or
Y is O, OH, OCOR2, halogen or cyano;
Z is CH2 or a covalent bond;
R is H or R2;
R1 is H, R2, phenyl, or COR2;
R2 is C1-C5 lower alkyl or alkenyl and R3 is benzothienyl, benzofuranyl, naphthyl or substituted derivatives thereof, wherein the substituents may
Type:
Grant
Filed:
January 16, 2003
Date of Patent:
July 27, 2004
Assignee:
Allergan, Inc.
Inventors:
Robert M. Burk, Mark Holoboski, Mari F. Posner
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
July 20, 2004
Assignee:
Allergan, Inc.
Inventors:
Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
Abstract: Compounds of the formula
where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
Type:
Grant
Filed:
February 4, 2003
Date of Patent:
July 6, 2004
Assignee:
Allergan, Inc.
Inventors:
Jayasree Vasudevan, Richard L. Beard, Haiqing Yuan, Roshantha A. Chandratratna
Abstract: Compounds of the formula
where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
Type:
Grant
Filed:
January 14, 2003
Date of Patent:
July 6, 2004
Assignee:
Allergan, Inc.
Inventors:
Richard L. Beard, Haiqing Yuan, Yang-Dar Yuan, Roshantha A. Chandraratna
Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell poliferation.
Type:
Grant
Filed:
March 13, 2003
Date of Patent:
June 8, 2004
Assignee:
Allergan, Inc.
Inventors:
Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;
wherein X, Y, Z, D and R3 are as defined in the specification.
Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
Abstract: Compounds of Formula 1:
wherein the variables are defined in the specification have cytochrome P450RAI-1 and P450RAI-2 inhibitory activity, and are suitable for treatment of mammals with conditions which are treatable with retinoids, or which are controlled by or responsive to the organism's native retinoic acid. Formulations containing the compounds of the invention can also be co-administered with retinoids and/or Vitamin A to enhance or prolong the effects of medications containing retinoids, Vitamin A, or of the organism's native retinoic acid.
Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;
wherein X, Y, Z, D and R3 are as defined in the specification.
Type:
Grant
Filed:
June 2, 2003
Date of Patent:
May 11, 2004
Assignee:
Allergan, Inc.
Inventors:
David W. Old, Thang D. Dinh, Robert M. Burk